Renal Function and Left Ventricular Ejection Fraction in Diabetic Patients with Acute Heart Failure
DOI:
https://doi.org/10.32734/sumej.v9i1.22989Keywords:
acute heart failure, cardio-kidney-metabolic syndrome, left ventricular ejection fraction, serum creatinine, type 2 diabetes mellitusAbstract
Background: Acute heart failure (AHF) in patients with type 2 diabetes mellitus (T2DM) is frequently complicated by renal dysfunction, which may aggravate cardiac impairment. Serum creatinine may reflect this cardio–renal interaction, but its association with left ventricular ejection fraction (LVEF) in AHF patients with T2DM remains unclear. Objective: To investigate the correlation between serum creatinine and left ventricular ejection fraction (LVEF) in patients with acute heart failure (AHF) and type 2 diabetes mellitus (T2DM). Methods: A cross-sectional study of 52 hospitalized AHF patients with T2DM. Clinical data, serum creatinine, A1C, and echocardiographic LVEF (assessed by two independent consultants) were collected. Correlation and multivariable linear regression analyses were performed. Results: The patients were middle-aged and predominantly male. Mean LVEF was 33.2 ± 9.1%, and mean serum creatinine was 1.58 ± 0.31 mg/dL. Higher serum creatinine levels were strongly associated with lower LVEF. Glycemic status (A1C) and urea levels also showed negative associations with LVEF. After adjustment, serum creatinine and A1C remained independent predictors of reduced LVEF. Conclusion: In AHF patients with T2DM, higher serum creatinine and A1C levels are independently associated with reduced LVEF, underscoring the cardio-renal-metabolic interplay in this population and highlighting the need for integrated management strategies.
Downloads
References
[1] Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.
[2] Sani MU, Davison BA, Cotter G, Mayosi BM. Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes mellitus. Cardiovasc J Afr. 2018;29(5):314–23.
[3] Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38.
[4] Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–78.
[5] Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36(23):1437–45.
[6] Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010;31(6):703–11.
[7] Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018;137(13):1391–406.
[8] Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71.
[9] Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(14):1823–38.
[10] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776–803.
[11] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
[12] Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293(5):572–80.
[13] Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137–55.
[14] Ganda A, Onat D, Demirkan B, et al. Renal dysfunction in heart failure with preserved ejection fraction: is it related to ejection fraction? Int J Cardiol. 2013;164(2):200–4.
[15] Kramer CK, Zinman B, Retnakaran R. Glycemic targets in type 2 diabetes mellitus: current status, challenges, and recent advances. Lancet Diabetes Endocrinol. 2021;9(7):451–66.
[16] Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115(1):79–96.
[17] Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the ESC, and Japanese Heart Failure Society. J Card Fail. 2021;27(4):387–413.
[18] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–200.
[19] McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
[20] Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.
[21] Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–27.
[22] Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9.
[23] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
[24] Docherty KF, Jhund PS, Claggett B, et al. Extrapolating long-term event-free and overall survival with dapagliflozin in patients with HFrEF. JAMA Cardiol. 2021;6(11):1298–1305 [cited 2025 Aug 13]. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2782791.
[25] Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
[26] Eagle KA; Boehringer Ingelheim. The EMPEROR-Reduced trial shows empagliflozin is superior to placebo in improving outcomes in HFrEF regardless of diabetes status. ACC.org. 2020 Aug 29 [cited 2025 Aug 13]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/08/29/19/36/the-emperor-reduced-trial-shows-empagliflozin-is-superior-to-placebo-in-improving-outcomes-in-hfref-regardless-of-diabetes-status.
[27] Packer M, et al. Full results from the EMPEROR-Reduced phase III trial: Jardiance (empagliflozin) reduced the risk of cardiovascular death and HF hospitalization; slowed kidney decline. Boehringer Ingelheim press release. 2020 Aug 29 [cited 2025 Aug 13]. Available from: https://www.boehringer-ingelheim.com/press-release/emperor-reduced-phase-iii-trial.
[28] Caffrey M. Empagliflozin cuts risk of CV, kidney events in heart failure regardless of CKD status. Am J Manag Care. 2020 Oct 24 [cited 2025 Aug 13]. Available from: https://www.ajmc.com/view/empagliflozin-cuts-risk-of-cv-kidney-events-in-heart-failure-regardless-of-ckd-status.
[29] Afsar B, Ortiz A, Covic A, et al. Focus on renal congestion in heart failure. Clin Kidney J. 2016;9(1):39–47 [cited 2025 Aug 13]. Available from: https://academic.oup.com/ckj/article/9/1/39/2693070.
[30] Zoccali C, Levin A, Mallamaci F, et al. Decongestion in patients with advanced chronic kidney disease coexisting with heart failure. Clin Kidney J. 2025;18(7): (in press) [cited 2025 Aug 13].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sumatera Medical Journal
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Sumatera Medical Journal (SUMEJ) and Faculty of Medicine as well as TALENTA Publisher Universitas Sumatera Utara as publisher of the journal.
Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, will be allowed only with a written permission from Sumatera Medical Journal (SUMEJ).
The Copyright Transfer Form can be downloaded here.
The copyright form should be signed originally and sent to the Editorial Office in the form of original mail or scanned document.
